Overview

An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapy

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This prospective, multi-center, observational study will evaluate the efficacy and the safety of MabThera (rituximab) in participants with rheumatoid arthritis who have not responded or have been intolerant to a first anti-TNF alpha therapy. Participants have commenced MabThera or an alternative anti-TNF alpha treatment as a second biological therapy. Data will be collected for 12 months.
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Adalimumab
Etanercept
Infliximab
Rituximab